Possible redundant data in the network meta-analysis of pharmacological therapies for opioid-induced constipation by Burr, NE & Ford, AC
This is a repository copy of Possible redundant data in the network meta-analysis of 
pharmacological therapies for opioid-induced constipation.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/126462/
Version: Accepted Version
Article:
Burr, NE orcid.org/0000-0003-1988-2982 and Ford, AC orcid.org/0000-0001-6371-4359 
(2018) Possible redundant data in the network meta-analysis of pharmacological therapies
for opioid-induced constipation. Journal of Pain and Symptom Management, 55 (3). e8-e9.
ISSN 0885-3924 
https://doi.org/10.1016/j.jpainsymman.2017.12.492
© 2018 Published by Elsevier Inc. on behalf of American Academy of Hospice and 
Palliative Medicine. This manuscript version is made available under the CC-BY-NC-ND 
4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
	
	


	
					



		
 !"!#!!#$%"&
% '
"!%!'$%"

(() #*++,-./012+3-***2*
4() 2* 2*2567 7 /*28 2/ 0./
$) 9#.5.-
:) Journal of Pain and Symptom Management
$;
	) /2/*28
	
	) /./*28
			)!"'
%"

	
				
	


		"	

	
	
	
	
1/*2+3"
)2* 2*2567 7 /*28 2/ 0./ 
:'
	
				
	 ;	
	;
	;		 :	


	"			"
;			
	 
			
	
	
;

				"


				7	 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
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Letter to the editors: 
We read with great interest the recent systematic review and network meta-analysis by 
Sridharan and Sivaramakrishnan, (1) which synthesised data from 23 separate articles reporting 
randomised controlled trials (RCTs) of pharmacological therapies for opioid-induced constipation 
(OIC). After pooling and analysing the results from these articles, the authors concluded that 
subcutaneous methylnaltrexone performed better than other medications for OIC.  
 We have some concerns about the accuracy of the results in this study. From the accepted 
manuscript, in Table 1 “Key characteristics of the included studies”, it appears that data from the 
same RCTs could have been entered into the meta-analysis more than once. The articles by Thomas 
et al.(2) and Chamberlain et al. (3) both report data from the same RCT investigating the efficacy of 
subcutaneous methylnaltrexone in 134 patients with OIC and advanced illness, conducted in the USA 
and Canada. Similarly, Iyer et al.(4) and Michna et al.(5) both report data from another trial 
investigating the efficacy of subcutaneous methylnaltrexone for OIC, recruiting 460 patients across 
multiple sites in the USA.  All four of these articles appear in the included studies table, and may 
have been included as separate, unrelated, RCTs in the network meta-analysis.  
If this is indeed the case, this would have serious implications for the results, and may well 
account for the fact that subcutaneous methylnaltrexone appeared significantly better than 
alternative pharmacological therapies for the treatment of OIC. It is impossible to know conclusively 
whether our suspicions are correct. The primary outcome of rescue-free bowel movement within 24 
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hours without laxation was drawn from 16 RCTs. The duplicate studies might not have been 
erroneously combined, but there are no references for each individual RCT that contributed data to 
each separate analysis. There is mention of “eight post-hoc studies or extension studies” being 
excluded in the PRISMA flow chart (Figure 1 of their article). However, neither of the studies by 
Chamberlain et al.(3) or Michna et al.(5) were identified as dual publications here by the authors, 
and thus excluded from the meta-analysis.  
 A systematic review and meta-analysis of RCTs is considered the highest level of evidence. 
(6) It is therefore important that data are synthesised accurately, and summarised in a reproducible 
way, as these studies are often used to guide clinical practice. It can be difficult for journal editors, 
peer reviewers and, not least, readers of these articles to confirm the accuracy of data included in 
them and therefore the veracity of the results, particularly when the authors’ standard of reporting 
of the data included in the meta-analysis is suboptimal. We would welcome clarification from the 
authors about the individual RCTs included in their analyses, in order to ascertain whether the effect 
observed in favour of subcutaneous methylnaltrexone is genuine.  
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